Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment.
Kamenicky P, Briot K, Brandi ML, Cohen-Solal M, Crowley RK, Keen R, Kolta S, Lachmann RH, Lecoq AL, Ralston SH, Walsh JS, Rylands AJ, Williams A, Sun W, Nixon A, Nixon M, Javaid MK.
Kamenicky P, et al. Among authors: briot k.
RMD Open. 2023 Feb;9(1):e002676. doi: 10.1136/rmdopen-2022-002676.
RMD Open. 2023.
PMID: 36854566
Free PMC article.
Clinical Trial.